Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2019

02.07.2019 | Clinical trial

The relationship between ring-type dedicated breast PET and immune microenvironment in early breast cancer

verfasst von: Shinsuke Sasada, Noriyuki Shiroma, Noriko Goda, Keiko Kajitani, Akiko Emi, Norio Masumoto, Takayuki Kadoya, Koji Arihiro, Morihito Okada

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

18F-fluorodeoxyglucose (FDG) uptake on positron emission tomography (PET) is related to the biological parameters and prognosis of breast cancer. However, whether whole-body PET (WBPET) and dedicated breast PET (DbPET) can reflect the tumor microenvironment is unclear. This study investigated the relationship between stromal tumor-infiltrating lymphocytes (TILs) and maximum standardized uptake value (SUVmax) in WBPET and DbPET.

Methods

A total of 125 invasive breast cancers underwent WBPET and ring-type DbPET and resected specimens were pathologically assessed. The impact of SUVmax on the tumor biological parameters and TILs was retrospectively evaluated. SUVmax was classified as high and low relative to the median values (WBPET-SUVmax: 2.2 and DbPET-SUVmax: 6.0).

Results

SUVmax correlated with tumor size, nuclear grade, Ki-67 labeling index, and TILs in both WBPET and DbPET (all p < 0.001). In multiple linear regression analysis, tumor size, Ki-67 labeling index, and TILs predicted SUVmax in WBPET and DbPET. The cutoff values of tumor size, Ki-67 labeling index, and TILs predicting high SUVmax were 20 mm, 20%, and 20%, respectively. In multivariate analysis, the predictive factors for high SUVmax were tumor size and Ki-67 labeling index for WBPET and tumor size and TILs for DbPET. High SUVmax in DbPET was related to high numbers of TILs after propensity score matching analysis; however, WBPET was not (p = 0.007 and p = 0.624, respectively).

Conclusions

Both SUVmax values in WBPET and DbPET predicted TIL concentration of the primary breast cancer. In DbPET, SUVmax represented the immune microenvironment after adjusting for tumor biological factors.
Literatur
7.
Zurück zum Zitat Lopci E, Toschi L, Grizzi F, Rahal D, Olivari L, Castino GF, Marchetti S et al (2016) Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery. Eur J Nucl Med Mol Imaging 43(11):1954–1961. https://doi.org/10.1007/s00259-016-3425-2 CrossRef Lopci E, Toschi L, Grizzi F, Rahal D, Olivari L, Castino GF, Marchetti S et al (2016) Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery. Eur J Nucl Med Mol Imaging 43(11):1954–1961. https://​doi.​org/​10.​1007/​s00259-016-3425-2 CrossRef
11.
Zurück zum Zitat Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31(31):3997–4013. https://doi.org/10.1200/jco.2013.50.9984 CrossRefPubMed Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31(31):3997–4013. https://​doi.​org/​10.​1200/​jco.​2013.​50.​9984 CrossRefPubMed
Metadaten
Titel
The relationship between ring-type dedicated breast PET and immune microenvironment in early breast cancer
verfasst von
Shinsuke Sasada
Noriyuki Shiroma
Noriko Goda
Keiko Kajitani
Akiko Emi
Norio Masumoto
Takayuki Kadoya
Koji Arihiro
Morihito Okada
Publikationsdatum
02.07.2019
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2019
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-019-05339-0

Weitere Artikel der Ausgabe 3/2019

Breast Cancer Research and Treatment 3/2019 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.